Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
Antibody
France Strengthens Cancer Access with TEVIMBRA and New 14-Day Trial Fast-Track
Breaking Down TEVIMBRA Access and the 14-Day Trial Pathway France has taken two decisive steps to reinforce its clinical research ecosystem and expand access to new oncology therapies. The Haute Autorité de Santé (HAS) has issued a favourable reimbursement opinion for TEVIMBRA (tislelizumab) in gastric and oesophageal cancers, while the National Agency for the Safety … Read more
NICE Expands Cancer and Dermatology Options With Three Major Recommendations Across DLBCL, Myeloma, and Chronic Hand Eczema
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
ABL Bio’s Grabody lands record heigh $2.6B deal with Lilly
ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.